StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Up 7.2 %
AEZS opened at $2.09 on Tuesday. The company has a 50 day moving average of $2.00 and a two-hundred day moving average of $1.90. Aeterna Zentaris has a 52-week low of $1.36 and a 52-week high of $3.30. The company has a market cap of $10.16 million, a P/E ratio of -0.61 and a beta of 1.57.
Shares of Aeterna Zentaris are scheduled to reverse split on the morning of Friday, May 3rd. The 1-4 reverse split was announced on Friday, May 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Friday, May 3rd.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.
See Also
- Five stocks we like better than Aeterna Zentaris
- Russell 2000 Index, How Investors Use it For Profitable Trading
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Amazon Stands Tall: New Highs Are in Sight
- Dividend Payout Ratio Calculator
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.